Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,668
  • Shares Outstanding, K 6,575
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,200 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.80
  • Most Recent Earnings $-0.15 on 03/04/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.62
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +26.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6140 +14.12%
on 03/11/25
0.8236 -14.92%
on 02/27/25
-0.1337 (-16.02%)
since 02/26/25
3-Month
0.6140 +14.12%
on 03/11/25
1.3000 -46.10%
on 02/25/25
-0.3493 (-33.27%)
since 12/26/24
52-Week
0.6140 +14.12%
on 03/11/25
3.1000 -77.40%
on 04/15/24
-0.6643 (-48.67%)
since 03/26/24

Most Recent Stories

More News
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Secures Expanded Patent for Genotype-Based Treatment of Alcohol Use Disorder

Adial Pharmaceuticals receives a patent for expanded genotype coverage in treating alcohol use disorder with its drug AD04.Quiver AI SummaryAdial Pharmaceuticals, a clinical-stage biopharmaceutical company...

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

ADIL : 0.7007 (-1.31%)
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

ADIL : 0.7007 (-1.31%)

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 0.8035
2nd Resistance Point 0.7712
1st Resistance Point 0.7406
Last Price 0.7007
1st Support Level 0.6777
2nd Support Level 0.6454
3rd Support Level 0.6148

See More

52-Week High 3.1000
Fibonacci 61.8% 2.1503
Fibonacci 50% 1.8570
Fibonacci 38.2% 1.5637
Last Price 0.7007
52-Week Low 0.6140

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar